Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO 0.63%) were lower by 4% as of 11 a.m. ET today. The move comes as ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...